Avrobio Inc (NAS:AVRO)
$ 16.8 -0.02 (-1.41%) Market Cap: 62.85 Mil Enterprise Value: -27.41 Mil PE Ratio: 2.03 PB Ratio: 0.71 GF Score: 22/100

AVROBIO Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript

Oct 28, 2021 / 02:30PM GMT
Release Date Price: $66.72 (+3.54%)
Maury Raycroft
Jefferies Financial Group Inc. - Analyst

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Geoff MacKay, the CEO of AVROBIO. Thanks for joining us today, Geoff. I'll turn it over to you to tell everyone more about the Company. (Conference Instructions)

Geoff MacKay
AVROBIO, Inc. - President & CEO

Great. Thank you very much, Maury. Real pleasure to have the opportunity to present our Company to you. Before we begin, just highlight that the presentation will contain forward-looking statements based on our current expectations and beliefs, and I refer you to our SEC filings for further information.

The founding purpose of AVROBIO remains freedom from a lifetime of disease. And what that means to us and to our indications is ideally delivery of radically better outcomes for devastating diseases, number one, but number two, to untether patients from weekly or biweekly infusions, in other words to enable patients, people to reach their full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot